| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Norgine Announces Publication of the Prosper Study Design in the Hepatology, Medicine and Policy Journal[i]
By: PR Newswire Association LLC. - 29 Jan 2018Back to overview list

AMSTERDAM, January 29, 2018 /PRNewswire/ --

  • PROSPER is the first Norgine funded European and Australian real world evidence study of patients' experience with hepatic encephalopathy taking rifaximin-? 550mg 

Norgine B.V. today announced the publication of the study design of PROSPER (The Prospective Real-world Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-?) in the journal Hepatology Medicine and Policy. The study has been designed to monitor the clinical effectiveness of rifaximin-? and its impact on health care resources utilisations. PROSPER is an observational, multicentre study among 550 patients in Europe and Australia.

     (Logo: )

PROSPER will provide valuable real-world information on the effectiveness of rifaximin-? 550 mg in reducing the recurrence of hepatic encephalopathy, and its impact on the quality of life (QoL) and work productivity of patients and their caregivers. By providing data on both the direct costs (e.g., hospitalisation rate, duration of hospitalisation) and indirect costs (such as work productivity) of hepatic encephalopathy. PROSPER study findings are anticipated to report in 2018.

Dr Alastair Benbow, Chief Development and Medical Officer at Norgine said: "It is anticipated that the PROSPER study will continue to reinforce the value of rifaximin-? 550mg for all European and Australian patients and their health care systems. This will continue to emphasize that rifaximin-? 550mg can significantly reduce the number of emergency department attendances, with or without admission and lower the use of hospital resources and bed occupancy." 

Hepatic encephalopathy is a debilitating condition that affects up to 40% of patients across Europe who suffer from advanced chronic liver disease.[ii]

Media contact : Isabelle Jouin, T: +44(0)1895-453643

i. Krag et al.  Design of  the prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-? (PROSPER). Medicine and Policy (2018) 3:4 DOI10.1186/s41124-017-0029-9.

ii. American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases..J Hepatol. 2014;61(3):642-59.

Related companies:Norgine B.V.
Copyright 2018 PR Newswire Association LLC. Back to overview list
to the top ↑